The company's PM21 particle technology enables ex vivo expansion and activation of cytotoxic NK cells supporting multiple high-dose infusions, while its off-the-shelf NK-cell platform is based on NK cells from unique universal donors. Kiadis develops K-NK003 for the treatment of relapse/refractory acute myeloid leukemia, and K-NK002, which is administered as an adjunctive immunotherapeutic on top of HSCT.
Cyborg Score Rationale
Kiadis operates in a high-potential cell therapy market with differentiated NK-cell technology, but faces significant clinical development challenges and capital intensity typical of early-stage biopharmaceutical companies. The company's acquisition context and historical strategy shifts add execution risk.
Top Insights
Founded in 1997 in Amsterdam, Kiadis is an innovative biotechnology company specializing in the development of cell therapies for the treatment of blood cancer diseases.
The company's PM21 particle technology enables ex vivo expansion and activation of cytotoxic NK cells supporting multiple high-dose infusions.
The company has entered into a partnership with Sanofi to accelerate the development of its therapies.
NK-cell immunotherapy represents an adjacent approach to CAR-T therapies with potential off-the-shelf manufacturing advantages.
Named Competitors
Kymriah — CAR-T cell therapy for hematologic malignancies
Yescarta — CAR-T cell therapy for lymphoma and leukemia
Tecartus — CAR-T cell therapy for mantle cell lymphoma
Recent Developments
(2020) Sanofi offered to acquire Kiadis for €308 million plus potential milestone payments
(2019) Kiadis changed strategy to focus solely on development of Natural Killer (NK) cell therapeutics and terminated ATIR101 development
(2019) Kiadis announced formation of a Scientific Advisory Board
Open the full interactive Kiadis Pharma N.V. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.